Policy & Regulation


  • Image attribution tooltip
    George Marks via Getty Images

    PBMs under fire for drug prices defend their worth

    A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.

    By May 26, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    The UK-based company that's striving to overcome the limitations of T cell receptor innovation

    Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

    By Kim Ribbink • May 23, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    Ironwood Pharmaceuticals is charting a course to become a giant in GI

    Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market. 

    By May 19, 2022
  • Image attribution tooltip
    John Moore via Getty Images

    A potential COVID-19 EUA could turn this small biotech into a household name

    Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.

    By May 19, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Q&A

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    By Kelly Bilodeau • May 17, 2022
  • Image attribution tooltip
    iStock via Getty Images

    It's time to acknowledge access as a prescribing barrier

    A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs. 

    By May 11, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

    New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

    By Kelly Bilodeau • May 10, 2022
  • Image attribution tooltip

    Permission granted by Laura Randa. 

    Profile

    Laura Randa's aim to break down mental healthcare barriers for disabled patients

    Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.

    By Alexandra Pecci • April 27, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    By Kelly Bilodeau • April 26, 2022
  • Image attribution tooltip
    iStock via Getty Images
    Q&A

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    By Alexandra Pecci • April 21, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    The cannabis vanguard: A rare disease company looks to pioneer in the space

    Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

    By Jared Whitlock • April 21, 2022
  • Image attribution tooltip
    Andrey Bukreev via Getty Images

    A pharma mystery: Cancer-causing impurities drive joint search for answers

    Pharmaceutical industry insiders and regulators are striving to overcome the ‘blind spots’ that contribute to nitrosamine contamination.

    By April 19, 2022
  • Image attribution tooltip
    Justin Sullivan / Staff via Getty Images
    Q&A

    How pharma can up its social media game

    Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

    By April 18, 2022
  • Image attribution tooltip
    Permission granted by GoodRx
    Sponsored by GoodRx

    Inflation is forcing prioritization of healthcare spending — are you ready?

    Inflation means your customers' money doesn't travel as far as it did a few weeks ago.

    April 18, 2022
  • Image attribution tooltip
    Stock via Getty Images

    What now? Alzheimer's drugmakers ponder the path to approval

    Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

    By Kelly Bilodeau • April 14, 2022
  • Image attribution tooltip
    Yongyuan via Getty Images
    Q&A

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    By April 13, 2022
  • Image attribution tooltip
    Win McNamee/Staff via Getty Images

    How Congress could play a role in personalized medicine

    PGx — a tool to help determine proper dosing — may be poised to achieve broader use in healthcare and pharma.

    By Kelly Bilodeau • April 11, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Q&A

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    By Kim Ribbink • April 5, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

    A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

    By Kelly Bilodeau • March 23, 2022
  • Image attribution tooltip

    Permission granted by Anthony Mack.

    Virpax's CEO on leveraging new formulations to move drugs toward approval

    Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.

    By March 18, 2022
  • Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Q&A

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    By Kim Ribbink • March 14, 2022
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Q&A

    Ultragenyx's CEO on building a 'next-gen' rare disease company

    How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

    By Kim Ribbink • March 9, 2022
  • Image attribution tooltip

    Permission granted by Russell Potterfield.

    Profile

    From angel to operator: The unlikely journey of Endevica Bio's CEO

    Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

    By Jared Whitlock • March 9, 2022
  • Image attribution tooltip
    Stock via Getty Images

    QSAM's rare cancer treatment could be a game-changer

    For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.

    By Alexandra Pecci • Feb. 17, 2022
  • Image attribution tooltip
    Diego Camargo/PharmaVoice

    Welcome to the new PharmaVoice

    A similar mission, a new format, and our plans for PharmaVoice's next chapter.

    By Davide Savenije • Jan. 13, 2022